C07AB03 - Atenolol |
Not porphyrinogenic |
NP |
Rationale
Considerable clinical experience points to non-porphyrinogenicity.
Chemical description
Hydrophilic catecholamine derivative
Therapeutic characteristics
Selective antagonist of adrenergic beta1 adrenoceptors (beta blocker) for the treatment of e.g. hypertension, angina, dysrhythmias, myocardial infarction. Adverse reactions that can mimick porphyria symptoms are fatigue/muscle weakness, depression, sleep disturbance, gastrointestinal effects (nausea and vomiting, diarrhoea, constipation and abdominal cramping).
Hepatic exposure
Significant
Metabolism and pharmacokinetics
Less than 10% of an oral dose is metabolized, the rest being excreted in unchanged form in urine. 85 to 100 % of an intravenous dose is excreted unchanged in the urine.
Preclinical data
None
Personal communication
Used in Swedish porphyria ward:
IPNet drug reports
Uneventful use reported in 75 patients with acute porphyria.
References
- Scientific articles
- Mikolaenko MD, Conner MG. Pathologic quiz case. A 35 year old woman with a history of arrhythmia and liver failure. Arch Pathol Lab Med 2002;126(6):751-2. #1268
- Sneyd JR, Kreimer-Birnbaum M et al. Use of sufentanil and atracurium anesthesia in a patient with acute porphyria undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth 1995;9(1):75-8. #1267
Similar drugs
© NAPOS 2024